The 63 rating InvestorsObserver gives to Oncolytics Biotech, Inc. (ONCY) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, ONCYs 63 overall rating means the stock scores better than 63 percent of all stocks.
Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
Oncolytics Biotech, Inc. (ONCY) stock is lower by -2.7% while the S&P 500 has gained 0.33% as of 3:18 PM on Friday, Jan 8. ONCY is lower by -$0.07 from the previous closing price of $2.60 on volume of 1,437,755 shares. Over the past year the S&P 500 has gained 16.55% while ONCY is lower by -36.75%. ONCY lost -$0.82 per share the over the last 12 months.
Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
You May Also Like
See the original post here:
Is Oncolytics Biotech, Inc. (ONCY) The Right Choice in Biotechnology? - InvestorsObserver
Recommendation and review posted by G. Smith
